Jonathan B. Gill, MD
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Primary Appointment
Professor, Department of Pediatrics - Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor (Joint appointment), Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2001 | David Geffen School of Medicine at UCLA, Los Angeles, California, US, MD |
| 1997 | Harvard University, Cambridge, Massachusetts, US, BA in History and Science |
Postgraduate Training
| 2008-2009 | Special Fellow, Pediatric Hematology and Oncology, Memorial Sloan Kettering Cancer Center and New York Presbyterian/ Weill Cornell, Cornell, New York |
| 2005-2008 | Clinical Fellowship, Pediatric Hematology and Oncology, Memorial Sloan Kettering Cancer Center and New York Presbyterian/ Weill Cornell, Cornell, New York |
| 2001-2005 | Clinical Internship and Residency, Internal Medicine and Pediatrics, Mount Sinai Medical Center, New York, New York |
Licenses & Certifications
| 2017 | Texas Medical License |
| 2009 | Diplomate, American Board of Pediatrics, Hematology and Oncology |
| 2005 | Diplomate, American Board of Pediatrics |
| 2005 | Diplomate, American Board of Internal Medicine |
| 2003 | New York Medical License |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023
Extramural Institutional Committee Activities
Member, Research Proposal Selection and Faculty Nomination Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Human Subject Research Informatics Subcommittee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Clinical Research Committee #3, The University of Texas MD Anderson Cancer Center, 2018 - Present
Director, Pediatric Clinical Trials, The University of Texas MD Anderson Cancer Center, 2017 - Present
Co-leader, Pediatric Clinical Trials Team, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Clinical Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, IND Task Force, The University of Texas MD Anderson Cancer Center, 2017 - Present
Honors & Awards
| 2015 | Lewis Fraad Award for Excellence in the Teaching of Residents, Children’s Hospital at Montefiore |
| 2013 | Hyundai Scholar |
| 2007 - 2008 | Chief Fellowship, Memorial Sloan-Kettering Cancer Center |
| 2005 | Fellow of the Year, New York Presbyterian/ Weill Cornell |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2017. Novel Treatment Options for Osteosarcoma. Conference. Novel Treatment Options for Osteosarcoma. New York, NY, US.
- 2016. Provider Views on Local Control in Ewing Sarcoma of the Axial Skeleton. Conference. Provider Views on Local Control in Ewing Sarcoma of the Axial Skeleton. Atlanta, GA, US.
- 2016. Neutropenia: When to Worry. Conference. Neutropenia: When to Worry. New Rochelle, NY, US.
- 2016. Neutropenia: When to Worry. Conference. Neutropenia: When to Worry. Nyack, NY, US.
- 2015. Pediatric Oncology Provider Views on Biopsying Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Conference. Pediatric Oncology Provider Views on Biopsying Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Atlanta, GA, US.
- 2014. A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors. Conference. A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors. Tampa, FL, US.
- 2013. A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors. Conference. A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors. Tampa, FL, US.
- 2012. A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors. Conference. A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors. Tampa, FL, US.
- 2010. Immune (not Idiopathic) Thrombocytopenic Purpura. Conference. Immune (not Idiopathic) Thrombocytopenic Purpura. New York, NY, US.
National Presentations
- 2017. Poster Presentation: Introducing C-Myc into transformed mesenchymal stem cells and osteoblasts to recapitulate the osteosarcoma phenotype. Conference. Poster Presentation: Introducing C-Myc into transformed mesenchymal stem cells and osteoblasts to recapitulate the osteosarcoma phenotype. Washington, DC, US.
- 2017. Poster Presentation: Skp2 is a therapeutic target for human osteosarcoma and its expression is inhibited by flavokawain A, a kava chalcone. Conference. Poster Presentation: Skp2 is a therapeutic target for human osteosarcoma and its expression is inhibited by flavokawain A, a kava chalcone. Washington, DC, US.
- 2017. Poster Presentation: Identifying circulating tumor DNA in patients with osteosarcoma. Conference. Poster Presentation: Identifying circulating tumor DNA in patients with osteosarcoma. Washington, DC, US.
- 2017. Poster Presentation: ICAM-1 (CD54) is involved in the osteogenic differentiation of mesenchymal stem cells and affects the progression of osteosarcoma cells. Conference. Poster Presentation: ICAM-1 (CD54) is involved in the osteogenic differentiation of mesenchymal stem cells and affects the progression of osteosarcoma cells. Washington, DC, US.
- 2017. Poster Presentation: Stage 1 evaluation of multi-receptor tyrosine-kinase inhibitor lenvatinib in osteosarcoma patient derived mouse xenograft models. Conference. Poster Presentation: Stage 1 evaluation of multi-receptor tyrosine-kinase inhibitor lenvatinib in osteosarcoma patient derived mouse xenograft models. Washington, DC, US.
- 2016. Poster Presentation. Pediatric Oncology Provider Views on Biopsying Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Conference. Poster Presentation. Pediatric Oncology Provider Views on Biopsying Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Chicago, IL, US.
- 2016. Poster Presentation. The Role of Fine Needle Aspiration in Diagnosing Pediatric Malignancies (#735). Conference. Poster Presentation. The Role of Fine Needle Aspiration in Diagnosing Pediatric Malignancies (#735). Minneapolis, MN, US.
- 2016. Poster Presentation. HHLA2, a Novel Member of the B7 Family of Inhibitory Ligands, is Highly Expressed in Osteosarcoma. Conference. Poster Presentation. HHLA2, a Novel Member of the B7 Family of Inhibitory Ligands, is Highly Expressed in Osteosarcoma. New Orleans, LA, US.
- 2016. Poster Presentation. Flavokawain A and B from Kava Extract Exhibits Low Toxicity and Up-Regulates Tumor Suppressor miRNAs in Human Osteosarcoma Cells. Conference. Poster Presentation. Flavokawain A and B from Kava Extract Exhibits Low Toxicity and Up-Regulates Tumor Suppressor miRNAs in Human Osteosarcoma Cells. New Orleans, LA, US.
- 2016. Poster Presentation. The Effect of rhBMP-2 on in vitro Osteosarcoma Tumorigenesis and on Pulmonary Growth and Development. Conference. Poster Presentation. The Effect of rhBMP-2 on in vitro Osteosarcoma Tumorigenesis and on Pulmonary Growth and Development. New Orleans, LA, US.
- 2016. Poster Presentation. Evaluation of CD47 Expression and Effects of CD47-SIRPalpha Fusion Protein in Patients with Osteosarcoma. Conference. Poster Presentation. Evaluation of CD47 Expression and Effects of CD47-SIRPalpha Fusion Protein in Patients with Osteosarcoma. New Orleans, LA, US.
- 2016. Poster Presentation. Immune Infiltration and PD-L1 Expression in the Tumor Microenvironment are Prognostic in Osteosarcoma. Conference. Poster Presentation. Immune Infiltration and PD-L1 Expression in the Tumor Microenvironment are Prognostic in Osteosarcoma. New Orleans, LA, US.
- 2016. Mechanical analysis of vascularized fibular graft prosthetic composite (VFGOC) for hemipelvectomy reconstruction. Conference. Mechanical analysis of vascularized fibular graft prosthetic composite (VFGOC) for hemipelvectomy reconstruction, Singapore, US.
- 2016. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation resulted in cure of a 15 year old male with primary isolated CNS late onset familial hemophagocytic lymphohistiocytosis. Conference. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation resulted in cure of a 15 year old male with primary isolated CNS late onset familial hemophagocytic lymphohistiocytosis. Honolulu, HI, US.
- 2015. Poster Presentation. Surface Markers of Osteoblastic Differentiation from Mesenchymal Stem Cells. Conference. Poster Presentation. Surface Markers of Osteoblastic Differentiation from Mesenchymal Stem Cells. San Diego, CA, US.
- 2015. Poster Presentation. Utilizing Cell Surface Markers to Define the Stages of Osteoblast Differentiation. Conference. Poster Presentation. Utilizing Cell Surface Markers to Define the Stages of Osteoblast Differentiation. Philadelphia, PA, US.
- 2014. Poster Presentation. Targeted Therapy of Osteosarcoma with Radiolabeled Monoclonal Antibody to an Insulin-Like Growth Factor-2 Receptor (IGF2R). Conference. Poster Presentation. Targeted Therapy of Osteosarcoma with Radiolabeled Monoclonal Antibody to an Insulin-Like Growth Factor-2 Receptor (IGF2R). Berlin, Germany, US.
- 2014. Variability in the reported management of pulmonary metastases in osteosarcoma. Conference. Variability in the reported management of pulmonary metastases in osteosarcoma. Vancouver, Canada, US.
- 2014. Poster Presentation. Provider Management of Lung Metastases in Patients with Osteosarcoma. Conference. Poster Presentation. Provider Management of Lung Metastases in Patients with Osteosarcoma. San Diego, CA, US.
- 2013. Poster Presentation. Functional Characterization of Bone Morphogenetic Proteins (BMP) and Elucidation of Their Roles In The Pathogenesis of Osteosarcoma. Conference. Poster Presentation. Functional Characterization of Bone Morphogenetic Proteins (BMP) and Elucidation of Their Roles In The Pathogenesis of Osteosarcoma. New York, NY, US.
- 2013. Poster Presentation. Required Surgical Margins for Local Control in a Xenograft Osteosarcoma Murine Model With and Without Single or Dual Agent Chemotherapy. Conference. Poster Presentation. Required Surgical Margins for Local Control in a Xenograft Osteosarcoma Murine Model With and Without Single or Dual Agent Chemotherapy. San Francisco, CA, US.
International Presentations
- 2012. Poster Presentation. HER2 Expression is Not Prognostic in Osteosarcoma: A Report of a Children’s Oncology Group Prospective Biology Study. Conference. Poster Presentation. HER2 Expression is Not Prognostic in Osteosarcoma: A Report of a Children’s Oncology Group Prospective Biology Study. Prague, CZ.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | MD Anderson Sarcoma SPORE |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | To provide administrative and budgetary support to ensure the maximal success of the program |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2016 - 2017 |
| Title: | Preclinical Study of Lenvantinib in Combination with Everolimus in Osteosarcoma Patient Derived Xenograft Models |
| Funding Source: | Eisai Research Grant |
| Role: | Investigator |
| Date: | 2015 - 2016 |
| Title: | Using Circulating Tumor DNA as a Marker of Micro-metastatic Disease in Osteosarcoma |
| Funding Source: | New York Community Trust |
| Role: | Co-PI |
| Date: | 2015 - 2017 |
| Title: | COG Site PI, Children's Montefiore |
| Funding Source: | Children's Oncology Group |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Characterizing Osteosarcoma from the Cell of Origin and Mesenchymal Stem Cell Differentiation |
| Funding Source: | Hyundai Hope on Wheels |
| Role: | PI |
| Date: | 2012 |
| Title: | A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors |
| Funding Source: | Rally Foundation |
| Role: | PI |
| Date: | 2011 - 2022 |
| Title: | A Phase 1 Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors |
| Funding Source: | Pediatric Cancer Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Fritz, CD, Basta, AV, Gill, JB, Lewis, VO, Bird, JE, Austin, M. The Role of Sociodemographics in Pediatric, Adolescent and Young Adult Osteosarcoma. Journal of pediatric surgery 60(4), 2025. e-Pub 2025. PMID: 39908921.
- Fritz, CD, Basta, AV, Gill, JB, Lewis, VO, Bird, JE, Austin, M. Pediatric Ewing Sarcoma Presentation, Treatment, and Outcomes Across Sociodemographic Groups. Journal of Surgical Research 303:322-331, 2024. e-Pub 2024. PMID: 39396459.
- Desrosiers-Battu LR, Wang T, Reuther J, Miles G, Dai H, Jo E, Russell H, Raesz-Martinez R, Recinos A, Gutierrez S, Thomas A, Berenson E, Corredor J, Nugent K, Wyatt Castillo R, Althaus R, Littlejohn R, Gessay S, Tomlinson G, Gill J, Bernini JC, Vallance K, Griffin T, Scollon S, Lin FY, Eng C, Kulkarni S, Hilsenbeck SG, Roy A, McGuire AL, Parsons DW, Plon SE. Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39259914.
- Wu CC, Huang L, Zhang Z, Ju Z, Song X, Kolb EA, Zhang W, Gill J, Ha M, Smith MA, Houghton P, Morton CL, Kurmasheva R, Maris J, Mosse Y, Lu Y, Gorlick R, Futreal PA, Beird HC. Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models. Scientific Reports 14(1), 2024. e-Pub 2024. PMID: 39191826.
- Vuocolo B, Gutierrez AM, Robinson JO, Recinos AM, Desrosiers LR, Majumder MA, Bernini JC, Gill J, Griffin T, Tomlinson GE, Vallance K, McGuire AL, Parsons DW, Plon SE, Scollon S. Families' experiences accessing care after genomic sequencing in the pediatric cancer context: "It's just been a big juggle". J Genet Couns 33(6):1337-1350, 2024. e-Pub 2024. PMID: 38225886.
- Gill JB, Andersen C, Bradley J, Draper L, Garrington T, Gill J, Harrison D, Hayashi M, Heaton A, Holladay C, Lion A, Rajan A, Rozo B, Runco D, Salvador L, Ferguson V, Arnold R. In-person and virtual adaptation of an interprofessional palliative care communications skills training course for pediatric oncology clinicians. Research Square, 2023. e-Pub 2023. PMID: 37609163.
- Zaky, W, Ragoonanan, D, Batth, IS, Dao, L, Wang, J, Xia, X, Daw Bitar, N, Gill, JB, Khatua, S, Li, S. Automated Capture and Analysis of Circulating Tumor Cells in Pediatric, Adolescent and Young Adult Patients with Central Nervous System Tumors. Cancers 15(15), 2023. e-Pub 2023. PMID: 37568669.
- Mangum, R, Reuther, J, Sen Baksi, K, Gandhi, I, Zabriskie, RC, Recinos, A, Raesz-Martinez, R, Lin, FY, Potter, SL, Sher, AC, Kralik, SF, Mohila, CA, Chintagumpala, M, Muzny, DM, Hu, J, Gibbs, RA, Fisher, KE, Bernini, JC, Gill, JB, Griffin, T, Tomlinson, GE, Vallance, KL, Plon, SE, Roy, A, Parsons, DW. Circulating tumor DNA sequencing of pediatric solid and brain tumor patients. Pediatric hematology and oncology 40(8):719-738, 2023. e-Pub 2023. PMID: 37366551.
- Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
- Metts, JL, Trucco, M, Weiser, DA, Thompson, PA, Sandler, E, Smith, T, Crimella, J, Sansil, S, Thapa, R, Fridley, BL, Llosa, N, Badgett, T, Gorlick, R, Reed, D, Gill, JB. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors. Cancer medicine 12(4):4270-4281, 2023. e-Pub 2023. PMID: 36151773.
- Harrison, DJ, Gill, JB, Roth, M, Hingorani, P, Zhang, W, Teicher, BA, Earley, EJ, Erickson, S, Gatto, GJ, Kumasheva, R, Houghton, PJ, Smith, M, Kolb, EA, Gorlick, R. Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. Pediatric Blood and Cancer 70(1), 2023. e-Pub 2023. PMID: 36250964.
- Beird, H, Bielack, S, Flanagan, AM, Gill, JB, Heymann, D, Janeway, K, Livingston, JA, Roberts, RD, Strauss, SJ, Gorlick, R. Osteosarcoma. Nature Reviews Disease Primers 8(1), 2022. e-Pub 2022. PMID: 36481668.
- Hingorani P, Zhang W, Zhang Z, Xu Z, Wang WL, Roth ME, Wang Y, Gill JB, Harrison DJ, Teicher BA, Erickson SW, Gatto G, Kolb EA, Smith MA, Kurmasheva RT, Houghton PJ, Gorlick R. Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, is effective in pediatric solid tumors: A report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther 21(8):1318-1325, 2022. e-Pub 2022. PMID: 35657346.
- Wang, Y, Tian, X, Zhang, W, Zhang, Z, Segura Lazcano, R, Hingorani, P, Roth, M, Gill, JB, Harrison, DJ, Xu, Z, Jusu, S, Kannan, S, Wang, J, Lazar, A, Earley, EJ, Erickson, S, Gelb, T, Huxley, P, Lahdenranta, J, Mudd, G, Kurmasheva, RT, Houghton, PJ, Smith, M, Kolb, EA, Gorlick, R. Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Molecular cancer therapeutics 21(6):903-913, 2022. e-Pub 2022. PMID: 35312779.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. e-Pub 2021. PMID: 33731864.
- Cuglievan B, Berkman A, Dibaj S, Wang J, Andersen CR, Livingston JA, Gill J, Bleyer A, Roth M. Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. J Adolesc Young Adult Oncol 10(2):164-174, 2021. e-Pub 2021. PMID: 32678703.
- Hingorani P, Roth ME, Wang Y, Zhang W, Gill JB, Harrison DJ, Teicher B, Erickson S, Gatto G, Smith MA, Kolb EA, Gorlick R. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther 20(3):535-540, 2021. e-Pub 2021. PMID: 33298592.
- Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson SW, Gatto G, Smith M, Kolb EA, Gorlick R. Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatr Hematol Oncol 38(1):1-6, 2021. e-Pub 2021. PMID: 32804009.
- Zvi Y, Ugur E, Batko B, Gill J, Roth M, Gorlick R, Hall D, Tingling J, Barkauskas DA, Zhang J, Yang R, Hoang BH, Geller DS. Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma 2021:8324348, 2021. e-Pub 2021. PMID: 33603563.
- Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw N, Li S. Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Front Oncol 11:760267, 2021. e-Pub 2021. PMID: 34956881.
- Batth IS, Dao L, Satelli A, Mitra A, Yi S, Noh H, Li H, Brownlee Z, Zhou S, Bond J, Wang J, Gill J, Sholler GS, Li S. Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. Int J Cancer 147(12):3550-3559, 2020. e-Pub 2020. PMID: 32506485.
- Gill J, Zhang W, Zhang Z, Roth M, Harrison DJ, Rowshan S, Erickson S, Gatto G, Kurmasheva R, Houghton P, Teicher B, Smith MA, Kolb EA, Gorlick R. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatr Blood Cancer 67(10):e28606, 2020. e-Pub 2020. PMID: 32706456.
- Harrison DJ, Gill JD, Roth ME, Zhang W, Teicher B, Erickson S, Gatto G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer 67(6):e28222, 2020. e-Pub 2020. PMID: 32207565.
- Sa HS, Rubin ML, Ning J, Li W, Tetzlaff MT, McGovern SL, Paulino AC, Herzog CE, Gill JB, Esmaeli B. Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma. JAMA Ophthalmol 138(4):374-381, 2020. e-Pub 2020. PMID: 32105303.
- Kinnaman MD, Zhu C, Weiser DA, Mohiuddin S, Hingorani P, Roth M, Gill J, Janeway KA, Gorlick R, Lessnick SL, Grohar PJ. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma 2020:3498549, 2020. e-Pub 2020. PMID: 33488267.
- Levine NL, Zhang Y, Hoang BH, Yang R, Jurkowski ZH, Roth ME, Gill JB, Lo Y, Eisenberg RE, Bekarev M, Gorlick R, Geller DS. LigaSure Use Decreases Intraoperative Blood Loss Volume and Blood Transfusion Volume in Sarcoma Surgery. J Am Acad Orthop Surg 27(22):841-847, 2019. e-Pub 2019. PMID: 30889038.
- Roth L, Moerdler S, Weiser D, Douglas L, Gill J, Roth M. Otolaryngologist and pediatric oncologist perspectives on the role of fine needle aspiration in diagnosing pediatric head and neck masses. Int J Pediatr Otorhinolaryngol 121:34-40, 2019. e-Pub 2019. PMID: 30861425.
- Geller DS, Levine NL, Hoang BH, Yang R, Weiser D, Morris J, Gorlick R, Gill JB, Roth ME, Tingling J, Brohl AS. Genomic Analysis Does Not Support Malignant Transformation of Osteoblastoma to Osteosarcoma. JCO Precis Oncol 3:1-7, 2019. e-Pub 2019. PMID: 32914027.
- Trucco M, Barredo JC, Goldberg J, Leclerc GM, Hale GA, Gill J, Setty B, Smith T, Lush R, Lee JK, Reed DR. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin. Pediatr Blood Cancer 65(9):e27224, 2018. e-Pub 2018. PMID: 29856514.
- Zhang Y, Zvi YS, Batko B, Zaphiros N, O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, Zhang W, Du X, Piperdi S, Liu Y, Zheng D, Roth M, Gill J, Zhang J, Ren T, Gorlick R, Zi X, Hoang BH. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Sci Rep 8(1):14294, 2018. e-Pub 2018. PMID: 30250282.
- Malbari F, Spira M, B Knight P, Zhu C, Roth M, Gill J, Abbott R, Levy AS. Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis: Impact of Family History. J Pediatr Hematol Oncol 40(6):359-63, 2018. e-Pub 2018. PMID: 29683959.
- Zhu C, Olson KA, Roth M, Geller DS, Gorlick RG, Gill J, Laack NN, Randall RL. Provider views on the management of Ewing sarcoma of the spine and pelvis. J Surg Oncol 117(3):417-424, 2018. e-Pub 2018. PMID: 29044582.
- Shaul E, Roth M, Lo Y, Geller DS, Hoang B, Yang R, Malkin D, Gorlick R, Gill J. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma. Cancer 124(6):1242-1250, 2018. e-Pub 2018. PMID: 29313943.
- Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Weiser DA. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget 9(16):12695-12704, 2018. e-Pub 2018. PMID: 29560102.
- Khazal S, Polishchuk V, Soffer G, Prinzing S, Gill J, Mahadeo KM. Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of late-onset primary isolated central nervous system hemophagocytic lymphohistiocytosis. Pediatr Transplant 22(1), 2018. e-Pub 2018. PMID: 29239076.
- Moody KM, Baker RA, Santizo RO, Olmez I, Spies JM, Buthmann A, Granowetter L, Dulman RY, Ayyanar K, Gill JB, Carroll AE. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatr Blood Cancer 65(1), 2018. e-Pub 2018. PMID: 28696047.
- Peterson HM, Hoang BH, Geller D, Yang R, Gorlick R, Berger J, Tingling J, Roth M, Gill J, Roblyer D. In vivo, noninvasive functional measurements of bone sarcoma using diffuse optical spectroscopic imaging. J Biomed Opt 22(12):1-9, 2017. e-Pub 2017. PMID: 29264893.
- Maxwell RR, Egan-Sherry D, Gill JB, Roth ME. Management of chemotherapy-induced febrile neutropenia in pediatric oncology patients: A North American survey of pediatric hematology/oncology and pediatric infectious disease physicians. Pediatr Blood Cancer 64(12), 2017. e-Pub 2017. PMID: 28748605.
- Morris J, Yang R, Roth M, Gill J, Gorlick R, Lo Y, Hoang BH, Garfein E, Geller DS. Mechanical analysis of the vascularized fibular graft prosthetic composite (VFGPC) for internal hemipelvectomy reconstruction. J Surg Oncol 115(7):864-869, 2017. e-Pub 2017. PMID: 28543392.
- Yang Y, Yang R, Roth M, Piperdi S, Zhang W, Dorfman H, Rao P, Park A, Tripathi S, Freeman C, Zhang Y, Sowers R, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R. Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. Genes Cancer 8(1-2):484-494, 2017. e-Pub 2017. PMID: 28435520.
- Gill J, Connolly P, Roth M, Chung SH, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Morris J, Gorlick R, Geller DS. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. PLoS One 12(3):e0173322, 2017. e-Pub 2017. PMID: 28264040.
- Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, Hoang B, Yang R, Roth M, Gill J, Gorlick R, Dadachova E. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol 43(12):812-817, 2016. e-Pub 2016. PMID: 27744117.
- Cohen B, Roth M, Marron JM, Gray SW, Geller DS, Hoang B, Gorlick R, Janeway KA, Gill J. Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Ann Surg Oncol 23(Suppl 5):990-997, 2016. e-Pub 2016. PMID: 27459981.
- Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, Zang X, Gorlick R. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep 6:31154, 2016. e-Pub 2016. PMID: 27531281.
- Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093, 2016. e-Pub 2016. PMID: 27456063.
- Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E, Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5(2):294-303, 2016. e-Pub 2016. PMID: 26714427.
- Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer 63(1):32-8, 2016. e-Pub 2016. PMID: 26305408.
- Geller DS, Gill J, Roth M, Gorlick R. To B(MP-2) or Not To B(MP-2): Cytokines and Tumor Surgery—Letter. Clin Cancer Res 21(17):4022, 2015. e-Pub 2015. PMID: 26330506.
- Geller DS, Singh MY, Zhang W, Gill J, Roth ME, Kim MY, Xie X, Singh CK, Dorfman HD, Villanueva-Siles E, Park A, Piperdi S, Gorlick R. Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. Clin Cancer Res 21(13):3003-12, 2015. e-Pub 2015. PMID: 25472999.
- Garfein E, Doscher M, Tepper O, Gill J, Gorlick R, Smith RV. Reconstruction of the pediatric midface following oncologic resection. J Reconstr Microsurg 31(5):336-42, 2015. e-Pub 2015. PMID: 25803408.
- Bhattasali O, Vo AT, Roth M, Geller D, Randall RL, Gorlick R, Gill J. Variability in the reported management of pulmonary metastases in osteosarcoma. Cancer Med 4(4):523-31, 2015. e-Pub 2015. PMID: 25626877.
- Poon VI, Roth M, Piperdi S, Geller D, Gill J, Rudzinski ER, Hawkins DS, Gorlick R. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res 5(1):4, 2015. e-Pub 2015. PMID: 25642322.
- Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer 61(9):1558-64, 2014. e-Pub 2014. PMID: 24753182.
- Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, Gill J, Gorlick R. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120(4):548-54, 2014. e-Pub 2014. PMID: 24166473.
- Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick R. Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One 9(8):e106249, 2014. e-Pub 2014. PMID: 25170759.
- Piperdi S, Austin-Page L, Geller D, Ahluwalia M, Gorlick S, Gill J, Park A, Zhang W, Li N, Chung SH, Gorlick R. β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells. Sarcoma 2012:164803, 2012. e-Pub 2012. PMID: 23125530.
- Amrani YM, Gill J, Matevossian A, Alonzo ES, Yang C, Shieh JH, Moore MA, Park CY, Sant'Angelo DB, Denzin LK. The Paf oncogene is essential for hematopoietic stem cell function and development. J Exp Med 208(9):1757-65, 2011. e-Pub 2011. PMID: 21844206.
- Weller E, Long N, Smith A, Williams P, Ravi S, Gill J, Henessey R, Skornik W, Brain J, Kimmel C, Kimmel G, Holmes L, Ryan L. Dose-rate effects of ethylene oxide exposure on developmental toxicity. Toxicol Sci 50(2):259-70, 1999. e-Pub 1999. PMID: 10478863.
Invited Articles
- Ferrari A, Gasparini P, Gill J, Gorlick R. Challenges of clinical management of adolescent and young adults with bone and soft tissue sarcoma. Cancer J 24(6):301-306, 2018. e-Pub 2018. PMID: 30480574.
- Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18(1):39-50, 2018. e-Pub 2018. PMID: 29210294.
- Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R, Reed D. Advances in therapy for pediatric sarcomas. Curr Oncol Rep 16(8):395, 2014. e-Pub 2014. PMID: 24894064.
- Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 137(1):89-99, 2013. e-Pub 2013. PMID: 22983152.
- Gill J. Inherited hematologic and oncologic syndromes. Pediatr Rev 32(9):401-4; discussion 404, 2011. e-Pub 2011. PMID: 21885666.
Review Articles
- Jia, Z, Ragoonanan, D, Mahadeo, KM, Gill, JB, Gorlick, R, Shpal, E, Li, S. IL12 immune therapy clinical trial review. Frontiers in immunology 13, 2022. e-Pub 2022. PMID: 36203573.
- Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 18(10):609-624, 2021. e-Pub 2021. PMID: 34131316.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
- Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KM. Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol 11:625707, 2021. e-Pub 2021. PMID: 33614514.
- Gill J, Hingorani P, Roth M, Gorlick R. HER2-Targeted Therapy in Osteosarcoma. Adv Exp Med Biol 1257:55-66, 2020. e-Pub 2020. PMID: 32483730.
- Bailey K, Roth M, Weiser D, J||B G. High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature. Sarcoma 2018:1948093, 2018. e-Pub 2018. PMID: 29853779.
- Serrano OK, Knapp E, Huang K, Baran G, Statter M, McClain D, Gill J. Pediatric primary splenic angiosarcoma: an aggressive multidisciplinary approach to the oncologic management of a rare malignancy. World J Surg Oncol 12(1):379, 2014. e-Pub 2014. PMID: 25487642.
Other Articles
- Beird, H, Bielack, S, Flanagan, AM, Gill, JB, Heymann, D, Janeway, K, Livingston, JA, Roberts, RD, Strauss, SJ, Gorlick, R Author Correction. Nature Reviews Disease Primers 8(1), 2022. PMID: 36585406.
Editorials
- Gill J, Gorlick R. Sarcomas With Complex Genetic Changes. Oncology Times 38(17):1,6,10-10, 2016.
Abstracts
- O’Donnell E, Batko B, Zvi Y, Gill J, Roth M, Gorlick R, Yang R, Hoang B, Geller D. Phenotypic characterization of IGFR2R knockout in human osteosarcoma cells. Connective Tissue Oncology Society Annual Meeting. Poster 018, Rome, Italy, 11/14/2018, 2018. e-Pub 2018.
- Batko B, Zvi Y, O’Donnell E, Sato K, X-Q D, Roth M, Gill J, Gorlick R, Lazar AJ, Yang R, Hoang B, Geller D. The development and characterization of a humanized xenograft murine model for osteosarcoma. Connective Tissue Oncology Society Annual Meeting. Poster 026. Rome, Italy. 11/14/2018, 2018. e-Pub 2018.
- Kurmasheva R, Bandyophadhyay A, Phelps D, Bondra K, Shackleford T, Michalek J, Zhang W, Roth M, Gill J, Gorlick R, Houghton P. Evaluation of lenvatinib, everolimus or the combination in pediatric sarcoma models. Connective Tissue Oncology Society Annual Meeting. Poster 0832. Rome, Italy. 11/14/2018, 2018. e-Pub 2018.
- Barris D, Fremed M, Dubin R, Gill J, Roth M, Hoang B, Gorlick R, Wesier D. Identifying circulating tumor DNA in patients with osteosarcoma. AACR. Poster Presentation. Washington, DC 2017, 2017. e-Pub 2017.
- Piperdi S, Zhang W, Gill J, Roth M, Gorlick R. Introducing C-Myc into transformed mesenchymal stem cells and osteoblasts to recapitulate the osteosarcoma phenotype. AACR. Poster Presentation. Washington, DC 2017, 2017. e-Pub 2017.
- Zhang W, Roth M, Gill J, Piperdi S, Gorlick R. Stage 1 evaluation of multi-receptor tyrosine-kinase inhibitor lenvatinib in osteosarcoma patient derived mouse xenograft models. AACR. Poster Presentation. Washington, DC 2017, 2017. e-Pub 2017.
- Lee JA, Hoang B, Yang R, Tingling J, Geller D, Fox JL, Gill J, Roth M, Gorlick R. The effect of surgical margins on local control for the treatment of Ewings sarcoma: A single institutional experience. Connective Tissue Oncology Society Annual Meeting. Maui, Hawaii. 11/8/2017, 2017. e-Pub 2017.
- Meeting Maui TTFPSIIHOCTOSA, 11/8/2017 H. Zaphiros N, Zvi Y, Hoang B, Geller D, Yang R, Du X, Zhang J, Gorlick R, Zhang W, Koirala P, Roth M, Gill J, Piperdi S, Zhang Y, 2017. e-Pub 2017.
- Zhang Y, Zhang W, Piperdi S, Roth M, Gill J, Gorlick R, Hoang B. Skp2 is a therapeutic target for human osteosarcoma and its expression is inhbited by flavokawain A, a kava chalcone. AACR. Poster Presentation. Washington, DC 2017, 2017. e-Pub 2017.
- Zhang Y, Zhang W, Piperdi S, Roth M, Gill J, Gorlick R. ICAM-1 (CD54) is involved in the osteogenic differentiation of mesenchymal stem cells and affects the progression of osteosarcoma cells. AACR. Poster Presentation. Washington, DC 2017, 2017. e-Pub 2017.
- Koirala P, Roth M, Gill J, Chinai J, Ewart M, Piperdi S, Geller D, Zang X, Gorlick R. HHLA2, a Novel Member of the B7 Family of Inhibitory Ligands, is Highly Expressed in Osteosarcoma. AACR. Poster Presentation. New Orleans, LA 2016, 2016. e-Pub 2016.
- Polishchuk V, Khazal S, Soffer G, Prinzing S, Gill J, Mahadeo KM. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation resulted in cure of a 15 year old male with primary isolated CNS late onset familial hemophagocytic lymphohistiocytosis, 2016. e-Pub 2016.
- Tannenbaum L, Moerdler S, Weiser D, Gill J, Roth M. The Role of Fine Needle Aspiration in Diagnosing Pediatric Malignancies. ASPHO. Poster Presentation. Minneapolis, MN 2016, 2016. e-Pub 2016.
- Zhang W, Morris J, Piperdi S, Guo Y, Ji T, Yang R, Roth M, Gill J, Geller D, Gorlick R, Hoang B. Flavokawain A and B from Kava Extract Exhibits Low Toxicity and Up-Regulates Tumor Suppressor miRNAs in Human Osteosarcoma Cells. AACR. Poster Presentation. New Orleans, LA 2016, 2016. e-Pub 2016.
- Piperdi S, Roth M, Morriss N, Zinone C, Geller D, Hoang B, Yang R, Gill J, Gorlick R. Evaluation of CD47 Expression and Effects of CD47-SIRPalpha Fusion Protein in Patients with Osteosarcoma. AACR. Poster Presentation. New Orleans, LA 2016, 2016. e-Pub 2016.
- Morris J, Yang R, Roth M, Gill J, Gorlick R, Hoang B, Garfein E, Geller D. Mechanical analysis of vascularized fibular graft prosthetic composite (VFGOC) for hemipelvectomy reconstruction. Asia Pacific Musculoskeletal Tumour Society. Singapore, 2016. e-Pub 2016.
- Geller D, Chung S, Zhang W, Piperdi S, Freeman C, Hoang B, Yang R, Roth M, Gill J, Gorlick R. The Effect of rhBMP-2 on in vitro Osteosarcoma Tumorigenesis and on Pulmonary Growth and Development. AACR. Poster Presentation. New Orleans, LA 2016, 2016. e-Pub 2016.
- Cohen B, Roth M, Marron J, Gray S, Geller D, Hoang B, Gorlick R, Janeway K, Gill J. Pediatric Oncology Provider Views on Biopsying Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. ASCO. Poster Presentation. Chicago, IL 2016, 2016. e-Pub 2016.
- Koirala P, Roth M, Gill J, Chinai J, Ewart M, Piperdi S, Geller D, Zang X, Gorlick R. Immune Infiltration and PD-L1 Expression in the Tumor Microenvironment are Prognostic in Osteosarcoma. AACR. Poster Presentation. New Orleans, LA 2016, 2016. e-Pub 2016.
- Koirala P, Poon V, Roth M, Piperdi S, Gill J, Gorlick R. Utilizing Cell Surface Markers to Define the Stages of Osteoblast Differentiation. Cancer Research 75((15 Supplement)):1412-1412, 2015. e-Pub 2015.
- Poon V, Roth M, Piperdi S, Gill J, Koirala P, Gorlick R. Surface Markers of Osteoblastic Differentiation from Mesenchymal Stem Cells. PAS. Poster Presentation. San Diego, CA 2015, 2015. e-Pub 2015.
- Bhattasali O, Vo AT, Roth M, Geller D, Randall RL, Gorlick R, Gill J. Variability in the reported management of pulmonary metastases in osteosarcoma. Pediatric Academic Society Annual Meeting, Vancouver, Canada. May 2014, 2014. e-Pub 2014.
- Vo A, Bhattasali O, Gill J, Roth M, Gorlick R. Provider Management of Lung Metastases in Patients with Osteosarcoma. AACR. Poster Presentation. San Diego, CA 2014, 2014. e-Pub 2014.
- Geller DS, Khan M, Revskaya E, Zhang W, Piperdi S, Park A, Hall C, Hoang B, Roth M, Gill J, Gorlick R, Dadachova E. Targeted Therapy of Osteosarcoma with Radiolabeled Monoclonal Antibody to an Insulin-Like Growth Factor-2 Receptor (IGF2R). Connective Tissue Oncology Society Annual Meeting. Berlin, Germany. Oct 15 – 18, 2014. Poster Presentation, 2014. e-Pub 2014.
- Geller DS, Berarev M, Piperdi S, Gill JB, Park A, Gorlick R. Required Surgical Margins for Local Control in a Xenograft Osteosarcoma Murine Model With and Without Single or Dual Agent Chemotherapy. The Musculoskeletal Tumor Society Annual Meeting Oct. San Francisco, CA. 3-5, 2013. Poster Presentation, 2013. e-Pub 2013.
- Gorlick R, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gorlick S, Gill J, Geller DS, Randall RL, Janeway K, Schwartz C, Grier H, Meyers P, Bernstein M, Marina N. HER2 Expression is Not Prognostic in Osteosarcoma: A Report of a Children’s Oncology Group Prospective Biology Study. Connective Tissue Oncology Society 17th Annual Meeting. Prague, Czech Republic. Nov 14 – 17, 2012. Poster Presentation, 2012. e-Pub 2012.
Book Chapters
- Geller DS, Gill J, Thornhill BA, Spierer M, Gorlick R. Osteosarcoma: A Multidisciplinary Approach. In: Sarcoma Oncology: A Multidisciplinary Approach. PMPH-USA, 2015.
- Gill J, Geller D, Gorlick R. HER-2 involvement in osteosarcoma. In: Adv Exp Med Biol, 161-77, 2014.
- Gill J, Geller D, Gorlick R. Personalized medicine and targeted therapy for osteosarcoma. In: Principles of Molecular Diagnostics and Personalized Cancer Medicine. Lippincott, Williams & Wilkins, 900-908, 2013.
- Gill, JB, Geller, D, Gorlick, R. Personalized medicine and targeted therapy for osteosarcoma, 900-908, 2012.
Patient Reviews
CV information above last modified March 19, 2026